Differential efficacy of different platelet glycoprotein iib/iiia antagonists on platelet/fibrin-mediated clot dynamics under different conditions using thrombelastography: The critical need for anticoagulant

Coronary Artery Disease

Volumn 13, Issue 4, 2002, Pages 243-248

  Mousa, Shaker A ^a   Forsythe, Mark S ^a   Bozarth, Jeffrey M ^a  

^a NONE   (United States)

Author keywords

Abciximab; Aggrastat; Calcium; Clot strength and retraction; Contact activation inhibitor; Integrilin; Orbofiban; Platelet aggregation; Platelet glycoprotein IIb IIIa antagonists; Roxifiban; Sibrafiban; Thrombelastography; Tissue factor

Indexed keywords

3 [[3 [4 (AMINOIMINOMETHYL)PHENYL] 4,5 DIHYDRO 5 ISOXAZOLYL]ACETAMIDO] N [(3,5 DIMETHYL 4 ISOXAZOLYL)SULFONYL]ALANINE; [[[3 [4 (AMINOIMINOMETHYL)PHENYL] 4,5 DIHYDRO 5 ISOXAZOLYL]ACETYL]AMINO] N [(3 METHYLPHENYL)SULFONYL]ALANINE; ABCIXIMAB; CALCIUM; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; LOTRAFIBAN; ORBOFIBAN; ROXIFIBAN; SIBRAFIBAN; THROMBOPLASTIN; TIROFIBAN; UNCLASSIFIED DRUG;

ANTICOAGULANT THERAPY; ARTICLE; BLOOD CLOT RETRACTION; CONTROLLED STUDY; DRUG EFFICACY; FIBRIN CLOT; HUMAN; HUMAN CELL; MOLECULAR DYNAMICS; PRIORITY JOURNAL; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOELASTOGRAPHY; THROMBOSIS;

ANTICOAGULANTS; BLOOD COAGULATION; FIBRIN; HUMANS; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; THROMBELASTOGRAPHY;

EID: 0036620763     PISSN: 09546928     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019501-200206000-00007     Document Type: Article

References (29)

1. Fuster V, Steele PM, Chesebro JH. Role of platelets and thrombosis in coronary atherosclerotic disease and sudden death. J Am Coll Cardiol 1985; 5:175B-184B.
2. Hamm CW, Bliefield W, Kupper W, Lorenz RL, Weber PC, Wober W. Biochemical evidence of platelet activation in patients with persistent unstable angina. J Am Coll Cardiol 1987; 10:998-1004.
3. Willerson JT, Golino P, Eidt J, Campbell WB, Buja LM. Specific platelet mediators and unstable coronary artery lesions. Experimental evidence and potential clinical implications. Circulation 1989; 21:198-205.
4. Pytela R, Pierschbacher MS, Ginsberg MH, Plow EF, Ruoslahti E. Platelet membrane glycoprotein IIb/IIIa: member of a family of RGD specific adhesion receptors. Science 1986; 231:1559-1562.
5. Topol EJ, Califf RM, Weisman HF, Ellis SG, Tcheng JE, Worley S, et al. (EPIC Investigators). Randomized trial of coronary intervention with antibody against platelet GPIIb/IIIa integrin for reduction of clinical restenosis: results at six months Lancet 1994; 343:881-886.
6. PRISM-PLUS Study Investigators Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. Platelet receptor inhibition in ischemic syndrome management in patients limited by unstable signs and symptoms. N Engl J Med 1998; 338:1488-1497.
7. Tcheng JE, Harrington RA, Kottke-Marchant K, Kleiman NS, Ellis SG, Kereiakes DJ, et al. (IMPACT Investigators). Multicenter, randomized, double-blind, placebo-controlled trial of the platelet integrin glycoprotein IIb/IIIa blocker, Integrilin in elective coronary intervention. Circulation 1995; 91:2151-2157.
8. Kleiman NS, Ohman EM, Califf RM, George BS, Kereiakes D, Aguirre FV, et al. Profound inhibition of platelet aggregation with monoclonal antibody c7E3 after thrombolytic therapy: results of the thrombolysis and angioplasty in myocardial infarction (TAMI) 8 pilot study. J Am Coll Cardiol 1993; 22:381-389.
9. Cohen K, Gerrard JM, White JG. Ultrastructure of clots during isometric contraction. J Cell Biol 1982; 93:775-483.
10. Brastn JV, Jerome WG, Hantgan RR. Uncoupling fibrin from integrin receptors hastens fibrinolysis at the platelet-fibrin interface. Blood 1994; 83:982-990.
11. Hantgan RR, Taylor RG, Lewis JC. Platelets interact with fibrin only after activation. Blood 1985; 65:1299-1308.
12. Reid TJ, Greilich PE, Carr ME, Alving BM. Quantitative clot retraction: a method assessing the function of fresh and stored platelets and GPIIb/IIIa receptors. Blood 1994; 84:1839-1847.
13. Mousa SA, Forsythe M, Lorelli W, Bozarth J, Xue C-B, Wityak J, et al. Novel nonpeptide antiplatelet GPIIb/IIIa receptor antagonist, DMP754: receptor binding affinity and specificity. Coron Artery Dis 1996; 7:767-774.
14. Mousa SA, Khurana S, Forsythe MS. Comparative in vitro efficacy of different platelet glycoprotein IIb/IIIa antagonists on platelet-mediated clot strength induced by tissue factor with use of thromboelastography: differentiation among glycoprotein IIb/IIIa antagonists. Arterioscler Thromb Vasc Biol 2000; 20:1162-1167.
15. Hantgan RR, Mousa SA. Inhibition of platelet-mediated clot retraction by integrin antagonist. Thromb Res 1998; 89:271-279.
16. Hartert H. Blutgerinnungstudien mit der Thromboelastograpie, einem ueuen Untersuchungsverfahren. Klin Wochenschrift 1948; 26:577-583.
17. Essel JH, Martin TJ, Salinas J, Thompson JM, Smith VC. Comparison of thromboelastography to bleeding time and standard coagulation tests in patients after cardiopulmonary bypass. J Cardiovasc Anesth 1993; 7:410-415.
18. Muller N, Popov-Cenic S, Buttner W, Kladetzky RG, Egil H. Studies of fibrinolytic and coagulation factors during open heart surgery. II. Postoperative tendency and changes in the coagulation system. Thromb Res 1975; 7:589-598.
19. Spiess BD, Tuman KJ, McCarthy RJ, DeLaria GA, Schillo R, Ivankovich AD. Thromboelastography as an indicator of postcardiopulmonary bypass coagulopathies. J Clin Monit 1987; 3:25-30.
20. Spiess BD, Gillies BS, Chandler W, Verrier E. Changes in transfusion therapy and re-exploration rate after institution of a blood management program in cardiac surgical patients. J Cardiothorac Vasc Anesth 1995; 9:168-173.
21. Simpfendorfer C, Kottke-Marchant K, Lowrie M, Anders RJ, Burns DM, Miller DP, et al. First chronic platelet glycoprotein IIb/IIIa integrin blockade: a randomized, placebo-controlled pilot study of Xemilofiban in unstable angina with percutaneous coronary interventions. Circulation 1997; 96:76-81.
22. Muller TH, Weisenberger H, Brickl R, Narjes H, Himmelsbach F. Profound and sustained inhibition of platelet aggregation by Fradafiban, nonpeptide platelet glycoprotein IIb/IIIa antagonist, and its orally active prodrug, Lefradafiban, in men. Circulation 1997; 96:1130-1138.
23. Cannon CP, McCabe CH, Borzak S, Henry TD, Tischler MD, Mueller HS, et al. Randomized trial of an oral platelet glycoprotein IIb/IIIa antagonist, sibrafiban, in patients after an acute coronary syndrome: results of the TIMI 12 trial. Thrombolysis in myocardial infarction. Circulation 1998; 97:340-349.
24. Harrington RA, Graffagnino C, Armstrong PW, Joseph D, Card TL, Sigmon KN, et al. Dose-finding and tolerability of a new oral platelet GPIIb/IIIa inhibitor, SB 214857, in patients with coronary artery and cerebrovascular disease: The APLAUD results. Circulation 1998; 98(suppl 17):1 1303.
25. Mousa SA, Topol EJ. Novel antiplatelet therapies: recent advances in the development of platelet gpiib/iiia receptor antagonists. In: Serruys PW, Holmes D, editors: Current review of interventional cardiology. 3rd ed. Philadelphia: Current Medicine; 1997. Vol. 13, pp. 114-129.
26. Mousa SA, Bozarth J, Lorelli W, Forsythe M, Thoolen M, Slee A, et al. Discovery of novel orally active non-peptide platelet GPIIb/IIIa receptor antagonist, DMP754: comparative platelet binding profiles with c7E3. J Pharmacol Exp Ther 1998; 286:1277-1284.
27. Mousa SA, Wityak J. Orally active Isoxazoline GPIIb/IIIa antagonists. Cardiovasc Drug Rev 1998; 16:48-61.
28. Cannon CP, McCabe CH, Wilcox RG, Langer A, Caspi A, Berink P, et al. Oral glycoprotein IIb/IIIa inhibition in patients with unstable coronary syndromes (OPUS-TIMI 16) trial. Circulation 2000; 102:149-156.
29. Greilich PE, Alving BM, Longnecker D, Carr ME, Jr, Whitten CW, Chang AS, et al. Near-site monitoring of the antiplatelet drug Abciximab using the Hemodyne analyzer and modified thrombelastograph. J Cardiothorac Vasc Anesth 1999; 13:58-64.